PT  - JOURNAL ARTICLE
AU  - Andrejko, Kristin L.
AU  - Pry, Jake
AU  - Myers, Jennifer F.
AU  - Openshaw, John
AU  - Watt, James
AU  - Birkett, Nozomi
AU  - DeGuzman, Jennifer L.
AU  - Li, Sophia S.
AU  - Barbaduomo, Camilla M.
AU  - Fang, Anna T.
AU  - Tran, Vivian H.
AU  - Javadi, Mahsa H.
AU  - Frost, Paulina M.
AU  - Dong, Zheng N.
AU  - Jain, Seema
AU  - Lewnard, Joseph A.
AU - on behalf of the California COVID-19 Case-Control Study Team
TI  - Predictors of SARS-CoV-2 infection following high-risk exposure
AID  - 10.1101/2021.10.20.21265295
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.20.21265295
4099  - http://medrxiv.org/content/early/2021/10/23/2021.10.20.21265295.short
4100  - http://medrxiv.org/content/early/2021/10/23/2021.10.20.21265295.full
AB  - Background Non-pharmaceutical interventions (NPIs) are recommended for COVID-19 mitigation. However, the effectiveness of NPIs in preventing SARS-CoV-2 transmission remains poorly quantified.Methods We conducted a test-negative design case-control study enrolling cases (testing positive for SARS-CoV-2) and controls (testing negative) with molecular SARS-CoV-2 diagnostic test results reported to California Department of Public Health between 24 February-26 September, 2021. We used conditional logistic regression to assess predictors of case status among participants who reported contact with an individual known or suspected to have been infected with SARS-CoV-2 (“high-risk exposure”) within ≤14 days of testing.Results 643 of 1280 cases (50.2%) and 204 of 1263 controls (16.2%) reported high-risk exposures ≤14 days before testing. Adjusted odds of case status were 2.94-fold (95% confidence interval: 1.66-5.25) higher when high-risk exposures occurred with household members (vs. other contacts), 2.06-fold (1.03-4.21) higher when exposures occurred indoors (vs. not indoors), and 2.58-fold (1.50-4.49) higher when exposures lasted ≥3 hours (vs. shorter durations) among unvaccinated and partially-vaccinated individuals; excess risk associated with such exposures was mitigated among fully-vaccinated individuals. Mask usage by participants or their contacts during high-risk exposures reduced adjusted odds of case status by 48% (8-72%). Adjusted odds of case status were 68% (32-84%) and 77% (59-87%) lower for partially- and fully-vaccinated participants, respectively, than for unvaccinated participants. Benefits of mask usage were greatest when exposures lasted ≥3 hours, occurred indoors, or involved non-household contacts.Conclusions NPIs reduced the likelihood of SARS-CoV-2 infection following high-risk exposure. Vaccine effectiveness was substantial for partially and fully vaccinated persons.KEY POINTSSARS-CoV-2 infection risk was greatest for unvaccinated participants when exposures to known or suspected cases occurred indoors or lasted ≥3 hours.Face mask usage when participants were exposed to a known or suspect case reduced odds of infection by 48%.Competing Interest StatementJAL discloses receipt of grants and honoraria from Pfizer, Inc. unrelated to this work.Funding StatementThe study was supported by the California Department of Public Health. JP, JO, and JFM were supported by a grant from the ELC program of the US CDC (program number 0187.0150). JAL was supported by NIH/NIAID (grant R01-AI14812701). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was granted a non-research determination by the State of California Health and Human Services Agency Committee for the Protection of Human Subjects (project number: 2021-034).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDirect data requests to the corresponding author at jlewnard{at}berkeley.edu